Abstract 1916P
Background
Dual ICI therapy is the standard of care for first-line PM patients (pts); single agent ICI improved survival vs placebo in pretreated pts. However, ICI efficacy is comprehensively unsatisfactory in PM, and no biomarkers predict response to therapy. We aimed to identify tumor features correlated with ICI efficacy in PM pts.
Methods
The NIBIT-EPI-MESO is a multicenter study led by the NIBIT Foundation in ICI-treated PM pts. Pts with irPR or irSD were classified as responders (R), those with irPD as non-responders (NR). Tumor biopsies underwent multi-omics analyses: RNA-seq, WES, RRBS, and multiplex immunofluorescence (mIF). Results were correlated with clinical outcome.
Results
Among 73 pts studied 54 had epithelioid, 16 biphasic, and 3 sarcomatoid PM; 64 received ICI as second/third line: 27 tremelimumab plus durvalumab (Calabrò, TLRM 2018), 36 nivolumab plus ipilimumab (Italian expanded access), 10 tremelimumab monotherapy (Calabrò, TLRM 2015). IrPR, irSD, and irPD were achieved by 27%, 36% and 37% of pts. Methylation profiling clustered pts into four subtypes: Demethylated, Low, Intermediate, and CIMP (hypermethylated). The Low cluster was enriched in R pts (22/41; p=0.01) who had the highest mOS (970 days), whereas the CIMP cluster was enriched in NR pts who had the worst mOS (288 days). Also, the Low cluster was the most predictive of ICI outcome in a multivariate model including sex, age, TMB, INFg gene expression (HR=0.1, CI: 0.02-0.47; p=0.003). An enriched proliferation and mitochondrial metabolism characterized the CIMP cluster, while the Low cluster was enriched in pathways associated with innate/adaptive immune response. The Low cluster had higher densities of tumor-associated CD8+ T (p=0.032) and CD20+ B cells (p=0.01) by mIF, compared to CIMP tumors. Tumor and stroma CD20+ B cells associated with response (p=0.016 and p=0.043), tumor CD4+ (p=0.009), CD8+ (p=0.01), CD68+(p=0.017) associated with OS. The low mutational rate identified did not associate with ICI response or OS.
Conclusions
Tumor methylation drives efficacy of ICI therapy in PM pts by shaping tumor immune contextures, regardless of PM histology and TMB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AIRC Foundation (ID.21073); Ministry of Health, Lombardy and Tuscany regions (NET-2016-02361632).
Disclosure
L. Calabro: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Roche, Merck Sharp Dohme; Financial Interests, Personal, Financially compensated role: Bristol Myers Squibb, AstraZeneca, Sanofi. F.P. Caruso, T. Noviello: Other, Personal, Stocks/Shares: Immunomics. A. Covre, S. Coral: Other, Personal, Stocks/Shares: Epigen Therapeutics. F. Grosso: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Novocure, Novartis, Pierre Fabre, Merck Sharp Dohme, PharmaMar. A.M. Di Giacomo: Financial Interests, Personal, Advisory Board: Pierre Fabre, GSK, Bristol Myers Squibb, Merck Sharp Dohme, Sunpharma, Immunocore, Sanofi; Financial Interests, Personal, Financially compensated role: Bristol Myers Squibb, Merck Sharp Dohme, Pierre Fabre, Sanofi. M. Ceccarelli: Other, Personal, Stocks/Shares: Immunomics; Financial Interests, Personal, Speaker, Consultant, Advisor: Moderna Therapeutics. M. Maio: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Pierre Fabre, Merck Serono, Amgen, Eli Lilly, Roche, Merck Sharp Dohme, Incyte, AstraZeneca, GSK, Sciclone, Sanofi, Alfasigma; Other, Personal, Stocks/Shares: Epigen Therapeutics, Theravance. All other authors have declared no conflicts of interest.
Resources from the same session
1534TiP - Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial
Presenter: Alfredo Budillon
Session: Poster session 18
1929P - Dabrafenib and trametinib (D+T) in BRAFV600E differentiated thyroid cancer: A real-world experience in Italy
Presenter: Laura Locati
Session: Poster session 18
1930P - Resensitization of BRAF-mutated radioactive iodine refractory differentiated thyroid cancer with longer duration of dabrafenib and trametinib
Presenter: Jiaxin Niu
Session: Poster session 18
1931P - Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
Presenter: Winston Wong
Session: Poster session 18
1932P - Tyrosine kinase inhibitors-induced erythrocytosis in thyroid cancers: A novel safety signal from a retrospective study
Presenter: Silvia Marchesi
Session: Poster session 18
1933P - Utility of circulating tumoral DNA analysis by multi-gene NGS panels in tracking therapy progression of advanced sporadic medullary thyroid carcinoma
Presenter: Raffaele Ciampi
Session: Poster session 18
1934P - Active surveillance for higher-risk papillary thyroid carcinoma in China: A 10-year retrospective study
Presenter: Yan Hu
Session: Poster session 18
1935P - Sequence matters: Impact of first-line response in overall therapeutic outcome in differentiated thyroid cancer. Data from the Spanish national registry of thyroid cancer (REGETNE-Tiroides)
Presenter: Sergio Pérez Fernandez
Session: Poster session 18